The 6-year cumulative incidence was estimated to be 4.28% (95% CI, 2.71–5.86) in the ILR group and 7.51% (95% CI, 6.26–8.76) in the control group among participants with NT-proBNP >15 pmol/L (Figure S3), corresponding to an absolute risk reduction of 3.23% and a number needed to screen to avoid one stroke/SE of 31 (ie, 100/3.23). This evidence concerns the gene NPPB and Stroke.